APA (7th ed.) Citation

S, K., D, Y., D, V. H., BJ, C., T, A., B, G., . . . P, F. (2025). Safety and effectiveness of fecal microbiota, live-jslm (REBYOTA®) administered by colonoscopy for prevention of recurrent Clostridioides difficile infection: 8-week results from CDI-SCOPE, a single-arm, phase IIIb trial. Therapeutic advances in gastroenterology, 18, 17562848251339697. https://doi.org/10.1177/17562848251339697

Chicago Style (17th ed.) Citation

S, Khanna, et al. "Safety and Effectiveness of Fecal Microbiota, Live-jslm (REBYOTA®) Administered by Colonoscopy for Prevention of Recurrent Clostridioides Difficile Infection: 8-week Results from CDI-SCOPE, a Single-arm, Phase IIIb Trial." Therapeutic Advances in Gastroenterology 18 (2025): 17562848251339697. https://doi.org/10.1177/17562848251339697.

MLA (9th ed.) Citation

S, Khanna, et al. "Safety and Effectiveness of Fecal Microbiota, Live-jslm (REBYOTA®) Administered by Colonoscopy for Prevention of Recurrent Clostridioides Difficile Infection: 8-week Results from CDI-SCOPE, a Single-arm, Phase IIIb Trial." Therapeutic Advances in Gastroenterology, vol. 18, 2025, p. 17562848251339697, https://doi.org/10.1177/17562848251339697.